|Source:||The roots of Panax ginseng C. A. Mey.|
|Biological Activity or Inhibitors:||1. (20S)-Protopanaxatriol shows strong and selective antimicrobial activity.
2. (20S)-Protopanaxatriol is the inhibitor of farnesyl-protein transferase.
3. (20S)-Protopanaxatriol exerts cardioprotective effects against myocardial ischemic injury, by enhancing the anti-free-radical actions of heart tissues.
4. (20S)-Protopanaxatriol has anti-oxidant activity, can inhibit the elevation of malondialdehyde content, the reduction of superoxide dismutase activity, glutathione peroxidase and total antioxIdant capacity.
|Solvent:||Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: firstname.lastname@example.org
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||2.0991 mL||10.4954 mL||20.9908 mL||41.9815 mL||52.4769 mL|
|5 mM||0.4198 mL||2.0991 mL||4.1982 mL||8.3963 mL||10.4954 mL|
|10 mM||0.2099 mL||1.0495 mL||2.0991 mL||4.1982 mL||5.2477 mL|
|50 mM||0.042 mL||0.2099 mL||0.4198 mL||0.8396 mL||1.0495 mL|
|100 mM||0.021 mL||0.105 mL||0.2099 mL||0.4198 mL||0.5248 mL|
J Pharm Biomed Anal. 2014 Jan;88:497-508.
|Identification of 20(S)-protopanaxatriol metabolites in rats by ultra-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry and nuclear magnetic resonance spectroscopy.[Pubmed: 24184656]|
|(20S)-Protopanaxatriol (PPT), one of the aglycones of ginsenosides, has been shown to exert cardioprotective effects against myocardial ischemic injury. However, studies on (20S)-Protopanaxatriol metabolism have rarely been reported. This study is the first to investigate the in vivo metabolism of (20S)-Protopanaxatriol following oral administration by ultra-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry (UPLC-Q/TOF-MS) and nuclear magnetic resonance (NMR) spectroscopy. The structures of the metabolites were identified based on the characteristics of their MS data, MS(2) data, and chromatographic retention times. A total of 22 metabolites, including 17 phase I and 5 phase II metabolites, were found and tentatively identified by comparing their mass spectrometry profiles with those of (20S)-Protopanaxatriol. Two new monooxygenation metabolites, (20S,24S)-epoxy-dammarane-3,6,12,25-tetraol and (20S,24R)-epoxy-dammarane-3,6,12,25-tetraol, were chemicallly synthesized and unambiguously characterized according to the NMR spectroscopic data. The metabolic pathways of (20S)-Protopanaxatriol were proposed accordingly for the first time. Results revealed that oxidation of (1) double bonds at Δ((24,25)) to form 24,25-epoxides, followed by rearrangement to yield 20,24-oxide forms; and (2) vinyl-methyl at C-26/27 to form corresponding carboxylic acid were the predominant metabolic pathways. Phase II metabolic pathways were proven for the first time to consist of glucuronidation and cysteine conjugation. This study provides valuable and new information on the metabolism of (20S)-Protopanaxatriol, which is indispensable for understanding the safety and efficacy of (20S)-Protopanaxatriol, as well as its corresponding ginsenosides.|
|Effect of 20(S)-protopanaxatriol and its epimeric derivatives on myocardial injury induced by isoproterenol.[Pubmed: 21528638]|
|OBJECTIVE: It was reported Panax ginseng had diverse components and multifaceted pharmacological functions. This study aims to investigate the effect of (20S)-Protopanaxatriol (PT, CAS 179799-20-3) and its epimeric derivatives (20S, 24R-epoxy-dammarane-3beta, 6alpha, 12beta, 25-tetraol, PTD1 and 20S, 24S-epoxy-dammarane-3beta, 6alpha, 12beta, 25-tetraol, PTD2) on myocardial injury induced by isoproterenol in rats. METHODS: Male Wistar rats were administered orally (20S)-Protopanaxatriol or its epimeric derivatives for 7 days. Four days after treatment, all rats, except those in the control group, were subcutaneously injected with isoproterenol (20 mg/kg) for 3 consecutive days. Two hours after the last isoproterenol injection, the rats were anaesthetized and sacrificed. The biochemical parameters were assayed and pathological examination of the heart tissues was performed. RESULTS: Administration of (20S)-Protopanaxatriol and PTD1 resulted in a reduction in creatine kinase and lactate dehydrogenase. (20S)-Protopanaxatriol and PTD1 Inhibited not only the elevation of malondialdehyde content, but also the reduction of superoxide dismutase activity, glutathione peroxidase and total antioxIdant capacity. The pathohistological changes induced by isoproterenol were also ameliorated by (20S)-Protopanaxatriol and PTD1. CONCLUSION: The present findings suggest that (20S)-Protopanaxatriol and PTD1 exerted cardioprotective effects against myocardial ischemic injury by enhancing the anti-free-radical actions of heart tissues. Furthermore the results indicated that the configuration of C-24 of the funan ring was involved in the phannacological action of the epimeric derivatives of (20S)-Protopanaxatriol.|